Therapeutic Drug Monitoring of Linezolid: a Retrospective Monocentric Analysis
Open accessThe DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Abstract
The objective of the present retrospective observational study carried out in patients receiving a standard dosage of linezolid and undergoing routine therapeutic drug monitoring (TDM) was to assess the interindividual variability in plasma exposure, to identify the prevalence of attainment of optimal pharmacodynamics, and to define if an intensive program of TDM may be warranted in some categories of patients. Linezolid plasma concentrations (trough [ C min ] and peak [ C max ] levels) were analyzed by means of a high-performance liquid chromatography (HPLC) method, and daily drug exposure was estimated (daily area under the plasma concentration-time curve [AUC 24 ]). The final database included 280 C min and 223 C max measurements performed in 92 patients who were treated with the fixed 600-mg dose every 12 h (q12h) intravenously ( n = 58) or orally ( n = 34). A wide variability was observed (median values [interquartile range]: 3.80 mg/liter [1.75 to 7.53 mg/liter] for C min , 14.70 mg/liter [10.57 to 19.64] for C max , and 196.08 mg·h/liter [144.02 to 312.10 mg·h/liter] for estimated AUC 24 ). Linezolid C min was linearly correlated with estimated AUC 24 ( r 2 = 0.85). Optimal pharmacodynamic target attainment (defined as C min of ≥2 mg/liter and/or AUC 24 /MIC 90 ratio of >80) was obtained in about 60 to 70% of cases, but potential overexposure (defined as C min of ≥10 mg/liter and/or AUC 24 of ≥400 mg·h/liter) was documented in about 12% of cases. A significantly higher proportion of cases with potential overexposure received cotreatment with omeprazole, amiodarone, or amlodipine. Our study suggests that the application of TDM might be especially worthwhile in about 30% of cases with the intent of avoiding either the risk of dose-dependent toxicity or that of treatment failure.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Prediction of Creatinine Clearance from Serum Creatinine
Cockcroft, D. W., & Gault, H. (1976) · Nephron · doi:10.1159/000180580 · Cited by 15,309 · cited 1×
“Creatinine clearance (CLCR) was estimated by means of the Cockcroft and Gault formula (5).”
MethodPharmacokinetic issues for antibiotics in the critically ill patient
Roberts, J. A., & Lipman, J. (2009) · Critical Care Medicine · doi:10.1097/ccm.0b013e3181961bff · Cited by 862 · cited 1×
“Additionally, considering the intrinsic characteristics of linezolid (a moderately lipophilic drug with mainly nonrenal, nonenzymatic clearance), it is expected that the pathophysiological changes occurring during sepsis should be less relevant than they would be for hydrophilic compounds, like the beta-lactams (29).”
BackgroundEffect of Obesity on the Pharmacokinetics of Drugs in Humans
Hanley, M. J., Abernethy, D. R., & Greenblatt, D. J. (2010) · Clinical Pharmacokinetics · doi:10.2165/11318100-000000000-00000 · Cited by 773 · cited 1×
“Indeed, we recognize that linezolid pharmacokinetics may be influenced by the degree of obesity, but considering that existing data for this patient demographic are quite sparse and variable (11, 19), no empirical alterations of linezolid dosage in obese patients can be suggested to date (19).”
BackgroundRayner, C. R., Forrest, A., Meagher, A. K., Birmingham, M. C., & Schentag, J. J. (2003) · Clinical Pharmacokinetics · doi:10.2165/00003088-200342150-00007 · Cited by 306 · cited 2×
“Additionally, it has been postulated that a Cmin higher than the MIC may be especially useful for linezolid efficacy in immunocompromised patients (24, 28).”
BackgroundFenner, K., Troutman, M., Kempshall, S., Cook, J., Ware, J., Smith, D., & Lee, C. (2009) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2008.195 · Cited by 272 · cited 1×
“Of note, in the present study patients experiencing linezolid overexposure were found to be more frequently cotreated with omeprazole, amiodarone, and/or amlodipine than were those with Cmins of 10 mg/liter, and all of these drugs are potent inhibitors of P-glycoprotein (P-gp) (7, 15, 20).”
BackgroundPai, M. P., & Bearden, D. T. (2007) · Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.27.8.1081 · Cited by 256 · cited 1×
“Indeed, we recognize that linezolid pharmacokinetics may be influenced by the degree of obesity, but considering that existing data for this patient demographic are quite sparse and variable (11, 19), no empirical alterations of linezolid dosage in obese patients can be suggested to date (19).”
BackgroundSlatter, J. G., Stalker, D. J., Feenstra, K. L., Welshman, I. R., BRUSS, J. B., Sams, J. P., Johnson, M. G., Sanders, P., Hauer, M. J., Fagerness, P. E., et al. (2001) · PubMed · Cited by 248
Interaction of omeprazole, lansoprazole and pantoprazole with P-glycoprotein
Pauli-Magnus, C., Rekersbrink, S., Klotz, U., & Fromm, M. F. (2001) · Naunyn-Schmiedeberg's Archives of Pharmacology · doi:10.1007/s00210-001-0489-7 · Cited by 230 · cited 1×
“Of note, in the present study patients experiencing linezolid overexposure were found to be more frequently cotreated with omeprazole, amiodarone, and/or amlodipine than were those with Cmins of 10 mg/liter, and all of these drugs are potent inhibitors of P-glycoprotein (P-gp) (7, 15, 20).”
BackgroundLinezolid: a review of safety and tolerability
Vinh, D. C., & Rubinstein, E. (2009) · Journal of Infection · doi:10.1016/s0163-4453(09)60009-8 · Cited by 213 · cited 3×
“in healthy volunteers (12, 32), might significantly increase the risk of dosedependent toxicity with linezolid (37).”
BackgroundPea, F., & Viale, P. (2009) · Critical Care · doi:10.1186/cc7774 · Cited by 194 · cited 1×
“In any case, the wide variability observed and the complex management of critically ill patients should induce clinicians to consider TDM an invaluable tool for the management of antibiotic therapy in this setting (22).”
BackgroundSelf-citation
Cited by
Antimicrobial therapeutic drug monitoring in critically ill adult patients: a Position Paper#
Abdul-Aziz, M. H., Alffenaar, J.-W. C., Bassetti, M., Bracht, H., Dimopoulos, G., Marriott, D., Neely, M. N., Paiva, J.-A., Pea, F., Sjovall, F., et al. (2020) · Intensive Care Medicine · doi:10.1007/s00134-020-06050-1 · Cited by 1,081
Self-citationRoberts, J. A., Abdul-Aziz, M. H., Lipman, J., Mouton, J. W., Vinks, A. A., Felton, T. W., Hope, W. W., Farkas, A., Neely, M. N., Schentag, J. J., et al. (2014) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(14)70036-2 · Cited by 1,046
From Therapeutic Drug Monitoring to Model‐Informed Precision Dosing for Antibiotics
Wicha, S. G., Märtson, A., Nielsen, E. I., Koch, B. C. P., Friberg, L. E., Alffenaar, J., Minichmayr, I. K., & the International Society of Anti‐Infective Pharmacology (ISAP), T. P. S. G. O. T. E. S. O. C. M. (2021) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.2202 · Cited by 322
Therapeutic drug monitoring of antimicrobials
Roberts, J. A., Norris, R., Paterson, D. L., & Martin, J. H. (2012) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2011.04080.x · Cited by 316
Moran, G. J., Fang, E., Corey, G. R., Das, A. F., De Anda, C., & Prokocimer, P. (2014) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(14)70737-6 · Cited by 309
Metadata
- Authors
- Pea, F., Furlanut, M., Cojutti, P., Cristini, F., Zamparini, E., Franceschi, L., & Viale, P.
- Venue
- Antimicrobial Agents and Chemotherapy
- Publisher
- American Society for Microbiology
- Published
- 2010-11
- Volume
- 54
- Issue
- 11
- Pages
- 4605-4610
- ISSN
- 0066-4804 (ISSN-L)
- 1098-6596
- OpenAlex
- W2118901469
- Cited by
- 198
- References
- 26
- FWCI
- 6.15
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.